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devastating condition. Molecular biological, biochemical 
and neuroimaging studies have yielded a substantial body 
of data on the causes and evolution of AD  [1–5] , whilst 
the concept of a vulnerable distributed brain network 
provides a framework for explaining how molecular 
events might scale up to a clinical phenotype  [6–9] . It is 
increasingly clear that AD has a protracted prodromal 
phase prior to clinical onset during which potentially 
pathogenic factors could operate and might have cumula-
tive effects  [5] .
 On a biochemical level, synaptic alterations are hy-
pothesised to play a key role in the pathogenesis of 
many neurodegenerative diseases, including AD  [9–11] . 
Such alterations may promote the transfer of pathogen-
ic molecular species (in particular, β-amyloid oligo-
mers) leading to the diffusive spread of misfolded pro-
teins (in particular, hyperphosphorylated tau) through-
out a vulnerable, distributed brain network, the so-called 
‘default mode network’ (DMN) that appears to be inte-
gral to the operation of the normal resting brain  [12–
16] . Most accounts of synaptic dysfunction in AD em-
phasise molecular and biochemical events impacting on 
synaptic physiology via a loss of structural integrity  [11, 
17] . However, an alternative (and by no means mutu-
ally exclusive) possibility is the promotion of synaptic 
damage by altered patterns of synaptic activity and ex-
citotoxicity  [18] . A fundamental example of a pervasive, 
phasic alteration in synaptic activity is the circadian 
sleep-wake cycle, which is associated with profound 
changes in many aspects of cellular and synaptic func-
tion  [19, 20] .
 Key Words 
 Sleep · Alzheimer’s disease · Neurodegeneration · Default 
mode network 
 Abstract 
 Background: Understanding the pathophysiology of Al-
zheimer’s disease (AD) is of fundamental importance for im-
proved diagnosis, monitoring and ultimately, treatment. Ob-
jective: A role for the sleep-wake cycle in the pathogenesis of 
AD has been proposed, but remains to be worked out in de-
tail.  Methods: Here we draw together several lines of previ-
ous work to outline a ‘hypnic hypothesis’ of AD.  Results: We 
propose that altered function of brainstem neuro transmitter 
pathways associated with sleep, promotes regio nally specific 
disintegration of a cortico-subcortical ‘default mode’ brain 
network that is selectively vulnerable in AD.  Conclusion: The 
formation of a dynamic toxic state within this vulnerable net-
work linked to sleep-wake disruption, would in turn lead to 
failure of synaptic repair, increased transmission of patho-
genic misfolded proteins and a self-amplifying neurodege-
nerative process. We consider the evidence for this hypnic 
hypothesis and the implications that follow on from it. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Understanding the pathophysiology of Alzheimer’s 
disease (AD) is of fundamental importance for improved 
diagnosis, monitoring and ultimately, treatment of this 
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 The precise implications of sleep-wake alterations for 
the pathogenesis of neurodegenerative diseases such as 
AD remain to be defined. However, converging evidence 
drawn from molecular biology, sleep neuroscience  [21–
34] and clinical neurology  [35–42] suggests that sleep 
may interact in diverse and important ways with the 
pathophysiology of AD. Ramifications of long-term dis-
ruption in the sleep-wake cycle could include synaptic 
overactivity and excitotoxicity  [10, 21, 43–45] , impaired 
synaptic pruning  [46] , failure of synaptic scaling and ho-
meostatic responses  [19, 20, 27, 47–51] , transmission of 
pathogenic proteins (β-amyloid and tau)  [9, 15, 16] , and 
disruption of neural circuitry in the vulnerable DMN  [6, 
8, 12, 21, 52, 53] . Such alterations might in turn underpin 
or contribute to the cognitive syndrome that character-
ises AD.
 A ‘Hypnic Hypothesis’ of AD 
 Although a role for the sleep-wake cycle in the patho-
genesis of AD has been proposed previously  [26, 33, 45, 
54] , this idea has received relatively little attention; how-
ever, it has become increasingly compelling in light of 
recent findings in human molecular and neuroimaging 
studies. Here we draw together several lines of previous 
work  [1, 2, 8, 10, 12–14, 21, 33, 35–37, 39, 42, 43, 55–67] 
to outline a hypnic hypothesis of AD pathophysiology. A 
prima facie case for the hypothesis rests on accumulating 
evidence that sleep-wake cycle disturbances are signifi-
cant in AD, and may track disease evolution  [35–37, 39, 
55, 58, 61, 62, 67] . The key features of the hypothesis we 
propose and predictions that follow from it are outlined 
in  table 1 and  figure 1 .
 Ascending neurotransmitter projection pathways play 
a key role in initiating and maintaining the brain state 
shifts that underpin sleep and wakefulness  [68] . Aminer-
gic and cholinergic pathways originating in brainstem nu-
clei govern thalamocortical activity changes that in turn 
evoke the cortical activity profile of physiological sleep 
stages  [59, 64] . During sleep, these ascending transmitter 
systems modulate the activity of key component areas 
within the DMN  [12, 13, 64] . The DMN includes the me-
sial temporal lobes and outflow projections to the poste-
rior cingulate, to the medial and inferior parietal and pre-
frontal cortices and their subcortical connections  [7, 12] . 
The core function of the network continues to be defined, 
but it is active during stimulus-independent thought in 
the resting wakeful (and dreaming) brain  [7, 59, 60] . Func-
tional alterations in the DMN have been consistently 
identified in neuroimaging studies  [6–8] of AD. Brain-
stem systems projecting to the DMN together with the 
DMN proper are likely to be integral to the development 
of AD; brainstem nuclei (in particular, the locus coerule-
us) and ascending neurotransmitter systems comprise the 
‘isodendritic core’ or reticular formation  [66] and are 
among the earliest targets of AD pathology  [1] .
 Emerging evidence suggests a fundamental, functional 
linkage between the neurobiology of sleep and AD. Sleep, 
in particular rapid eye movement (REM) sleep, is postu-
lated to have restorative effects on neuronal function  [67] 
and may promote synaptic efficiency  [21, 46] . The role 
played by this process has recently been emphasised as a 
guiding principle of brain operation in a novel account of 
sleep neurobiology proposed by Hobson and Friston 
 [46] . According to this account, ascending brainstem 
neurotransmitter systems interacting with components 
of the DMN are essential for maintaining and updating 
the brain’s internal model of the world by minimising re-
dundant complexity in synaptic networks. Such a generic 
sleep-related function would provide a mechanism link-
ing increased time awake due to sleep deprivation with 
inefficient synaptic firing and increased vulnerability of 
neural networks hosting these dysfunctional synaptic 
connections. As a core projection target of the neu-
rotransmitter pathways that mediate sleep-wake cycling, 
the DMN may be particularly susceptible to the effects of 
sleep disruption. Such selective susceptibility of the DMN 
is predicted by the hub vulnerability theory, according to 
which synaptic overactivity facilitates neurodegeneration 
 [21, 43] . Synaptic effects of sleep deprivation are unlikely 
to be restricted to a single pathophysiological mecha-
nism; for example, synaptic overactivity, inefficient prun-
ing or remodelling of redundant synapses and perturbed 
synaptic scaling and homeostasis might all operate within 
the DMN over different timescales and would be mutu-
ally reinforcing.
 While sleep promotes complexity reduction and the 
regulation of redundant synaptic connections, ongoing 
involvement of the DMN in these processes during wake-
fulness is very likely on anatomical grounds. If correct, 
this account would therefore place the DMN and its mod-
ulation by sleep at the foreground of brain function across 
the circadian cycle both in health and in AD. A disease 
state such as AD that initially damages sleep control 
mechanisms in the isodendritic core would have poten-
tially widespread and cumulative effects on synaptic 
function in the core and its projection zones in the DMN 
 [66] . In particular, if the dynamic toxic state generated 
within the network and the associated failure of synaptic 
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repair lead to accumulation and transmission of patho-
genic misfolded proteins, then neural damage would in 
time become self-amplifying and self-perpetuating (see 
 fig. 1 ).  [10, 21, 24] .
 We now consider the evidence for the hypothesis and 
its implications in more detail.
 Evidence for the Hypothesis: Sleep Alterations in AD 
 A hypnic hypothesis of AD requires, firstly, that sleep 
disturbance should form part of the early clinical pheno-
type. Indeed, though difficult to study rigorously outside 
specialised sleep laboratories, substantial evidence sug-
Table 1.  Key features, predictions and proposed tests of the hypnic hypothesis of AD
Features Predictions Tests
Systems level
– Pathology in brainstem 
pathways critical for 
sleep-wake and circadian 
physiology
–
–
–
Pathological changes in brainstem nuclei 
implicated in circadian control
Dysfunction and degeneration of 
ascending neurotransmitter pathways
Altered sleep/circadian physiology
–
–
–
–
Histopathological analyses in presymptomatic 
subjects
Functional, tractographic studies of brainstem 
pathways
Longitudinal sleep analysis in presymptomatic 
subjects
Animal models (especially transgenic)
– Sleep disruption drives 
subsequent 
neurodegeneration
– Disrupted sleep/circadian patterns early in 
clinical course precedes cognitive decline, 
cortical dysfunction and atrophy
–
–
–
–
Longitudinal sleep analyses in presymptomatic 
subjects with parallel neuroimaging
Early intervention to ameliorate sleep disruption 
Epidemiological studies assessing effects of 
premorbid neuronal activity (e.g. occupation, 
educational attainment) 
Animal models (especially transgenic)
– DMN neurodegeneration 
linked with sleep 
disruption 
– Specific DMN dysfunction, disintegration 
correlated with sleep/brainstem indices
– Functional, structural neuroimaging of DMN 
against behavioural indices in relation to sleep 
analyses
– REM sleep is an active 
‘rescue’ state
– REM deprivation and augmentation effects 
on cognitive/neuronal function 
–
–
Sleep analyses in AD subjects
Animal models with selective REM deprivation
– Self-amplification of sleep 
disruption effects
– Neurodegeneration and sleep alteration 
accelerating in tandem
–
–
Longitudinal sleep analyses, cognitive tests, 
neuroimaging in AD subjects
Sleep parameters manipulated in animal models
Cellular level
– Sleep disruption drives 
pro-inflammatory and 
oxidant states
– Pro-inflammatory, pro-oxidant responses 
correlated with circadian indices
–
–
Animal models with biochemical studies
Human plasma studies
– Sleep disruption drives 
protein misfolding and 
accumulation
– β-amyloid, tau levels correlated with 
circadian indices
–
–
Interstitial and CSF β-amyloid and tau levels 
Pathological studies with regional quantitation
– Cellular miscommuni-
cation drives neurode-
generation
– Persistent patterns of altered synaptic 
activity drives neurodegeneration
–
–
Manipulate environment and neurochemistry 
(animal models)
Synthetic neural networks modelling sleep stage 
activity
Molecular level
– Altered expression of cir-
cadian genes predisposes 
to neurodegeneration
– Altered expression profiles of (e.g. 
circadian clock) gene effects on 
neurodegeneration
–
–
Genomic, endophenotypic analyses
Transgenic animal models
– AD-related genes produce 
circadian alterations
– Primary alterations in circadian indices in 
at-risk individuals
– Sleep analyses in at-risk young subjects
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 Fig. 1. A schematic representation of the hypnic hypothesis of AD 
pathophysiology. The panels show non-sleep-deprived ( a ) and 
sleep-deprived ( b ) states. The circadian cycle is shown in simpli-
fied form comprising awake, REM sleep and non-REM sleep phas-
es (state transitions shown as bidirectional, open arrows). The 
brain in each state is represented in a stylised mid-sagittal section. 
 a  Non-sleep-deprived state. Key components of the DMN and its 
subcortical projections implicated in AD are shown in grey; other 
areas playing a critical role in sleep physiology and linked to DMN 
are also shown. IC = Isodendritic core in the upper brainstem; 
mTL = medial temporal lobe; mPFC = medial prefrontal cortex 
(here including anterior cingulate); PC = posterior cingulate/pre-
cuneus; h = hypothalamus; thal = thalamus. According to the 
hypnic hypothesis of AD, the non-sleep-deprived state is associ-
ated with an equilibrium between processes associated with in-
creased synaptic activity that promote neurodegeneration during 
waking and counteractive processes during the relatively tonically 
quiescent phase of non-REM sleep and an active ‘rescue’ phase of 
synaptic remodelling associated with REM sleep. Cumulative syn-
aptic dysfunction associated with waking directs pro-inflammato-
ry and pro-fibrillogenic alterations in anatomically restricted pro-
jection zones in the DMN (dotted arrows); these alterations are 
actively opposed especially during REM sleep (reversed dotted ar-
rows).  b Sleep-deprived state. In this state the net balance of effects 
favours neurodegeneration, and repair processes associated with 
sleep phases are inefficient or attenuated, with consolidation of 
neuronal damage leading ultimately to chronic neuronal dysfunc-
tion (cross-hatched grey areas) and frank neuronal loss (black ar-
eas).The topography of brainstem projections and inter-linked 
DMN regions gives rise to a specific anatomical evolution of AD 
pathology targeting the DMN (solid grey arrows). AD itself in-
duces sleep disruption due to early involvement of IC, leading to a 
toxic, self-amplifying and self-perpetuating state of chronic sleep 
disruption. Not shown explicitly in the figure is the spectrum of 
factors (including neurotransmitter and melatonin shifts and reac-
tive oxygen and inflammatory intermediates) associated with sleep 
disruption that further amplify and perpetuate the neurodegen-
erative process (see text for details). 
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gests that sleep-wake cycle disruption is a significant is-
sue detectable in early AD and becomes more severe 
with disease evolution. It has been proposed that chron-
ic sleep deprivation and associated neuronal overactivity 
may directly confer an increased risk of developing AD 
 [26] . Sleep disturbance is more frequent in patients with 
AD than the general population  [36] , occurring in some 
25–54% of patients overall  [54, 58] ; as this is based large-
ly on caregiver reports, it may be an underestimate. 
Sleep disturbance occurs early in the course of disease 
 [61] and worsens as disease evolves  [27, 69] , though not 
necessarily in a simple monotonic relation  [39, 63] . Sleep 
disruption is an important determinant of institution-
alisation in later-stage disease  [42] . Normal ageing is as-
sociated with increased sleep latency and frequent night 
time awakenings  [24] leading to increased daytime 
sleepiness  [36, 37] , features which are exaggerated in AD 
 [39] . AD is associated with decreased slow-wave sleep 
and REM sleep, prolonged REM latency, increased pro-
portions of stages I and II sleep, and increased fragmen-
tation of sleep, leading to an overall decrease in sleep 
duration  [36, 39] . Even after accounting for the effects 
of increased sleep fragmentation, AD is also associated 
with shifts in the normal circadian alertness profile (con-
tributing to ‘sundowning’ in later-stage disease)  [35–
37] , consistent with a specific impairment of circadian 
pacemaker function. 
Very little information is currently available con-
cerning dream morphology in AD. Nightmares can be 
a prominent feature of treatment with cholinesterase 
 inhibitors, although the mechanism is debated  [70, 71] . 
Alteration in several sleep parameters correlates with 
measures of performance across cognitive domains in 
AD  [37, 39] , suggesting a pervasive effect on cognitive 
function.
 An obvious question in this situation is whether the 
correlation of increased cognitive dysfunction and sleep 
disruption in AD might simply reflect the known cog-
nitive effects of sleep deprivation. This seems unlikely 
as the cognitive effects of sleep deprivation are atten-
uated during normal ageing  [69] , while the cognitive 
parameters linked to sleep disturbance in AD mirror 
the typical cognitive profile of the disease  [37, 39] . More 
direct evidence linking sleep disturbance with subse-
quent neurodegeneration has been obtained in animal 
models; alterations of REM sleep and circadian archi-
tecture similar to those in human AD patients precede 
deposition of amyloid plaques in APP transgenic mice 
 [25] .
 Evidence for the Hypothesis: The Neurobiology of 
Sleep 
 A second line of evidence linking sleep pathophysiol-
ogy with development of AD pathology rests on the com-
mon involvement of brainstem neurotransmitter systems 
in these processes. The normal sleep-wake cycle is gov-
erned by the interaction of neurochemical (in particular, 
cholinergic and aminergic) systems in the upper brain-
stem, hypothalamus and basal forebrain and their sub-
cortical and cortical projections. The cholinergic fore-
brain innervation originates mainly in the basal nucleus 
of Meynert and the noradrenergic innervation in the lo-
cus coeruleus  [63] . Together with orexin released by the 
posterolateral hypothalamus, the ascending pathways 
diffusely promote wakefulness; GABA- and galanin-me-
diated inhibition of these pathways by the rostral hypo-
thalamus triggers sleep onset, while mutual inhibition be-
tween pathways regulates transitions among sleep stages 
 [68] . The circuitry mediating sleep-wake transitions is 
modulated by signals sent from the circadian pacemaker 
in the suprachiasmatic nucleus and by humoral factors 
(in particular, melatonin), allowing entrainment with en-
vironmental factors such as the day-night cycle  [68] . The 
neuronal systems mediating the circadian cycle project to 
areas within the DMN  [63, 66, 72, 73] .
 The stages of sleep and wakefulness have characteristic 
electrophysiological signatures, reflecting underlying 
thalamocortical activity patterns: non-REM sleep is asso-
ciated with slow delta and ‘spindle’ activity due to oscilla-
tory firing of thalamic neurons and synchronised cortical 
activity, while wakefulness and REM sleep are associated 
with thalamocortical desynchronisation  [46, 64, 68] . 
Functionally, non-REM sleep is likely to be crucial for 
memory consolidation and synaptic regulation more 
generally  [74] , while REM sleep may serve to develop and 
maintain normal waking consciousness by building an 
internal predictive ‘model’ of the world that can then be 
tested and refined in response to waking sensory experi-
ence  [46, 65] . The noradrenergic locus coeruleus fires 
maximally during wakeful states, decreases its activity 
during non-REM sleep and is silent during REM sleep 
 [68] . The serotonergic dorsal raphe nucleus also fires 
maximally during wakefulness and suppresses REM sleep 
 [68] . Cholinergic neurons in the pons and basal forebrain 
fire during wakefulness and REM sleep  [54] . Acting to-
gether via their specific effects on sleep stage transitions, 
multiple parallel ascending neurotransmitter systems 
modulate behavioural arousal, allowing programming of 
flexible motor and affective responses to the internal mi-
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lieu and the external environment  [68] . Endogenous cir-
cadian pacemaker effects on cognition and behaviour in-
teract with (but are partly separable from) the effects of 
elapsed wakefulness and sleep periods per se  [75] . This 
complex neurochemical milieu would also provide sub-
strates to link sleep-wake alterations with mood altera-
tions and AD  [40, 42] . 
 In human functional neuroimaging studies, both non-
REM and REM sleep are associated with complex, phasic, 
regionally specific profiles of cortical activity changes  [51, 
59] . Non-REM sleep is associated with tonic deactivation 
of brainstem, thalami, cingulate, mesial temporal and 
prefrontal areas; however, non-REM slow-wave activity 
is associated with increased activation of brainstem, ven-
tral prefrontal, posterior cingulate/precuneus and para-
hippocampal areas  [51, 59] . Sleep spindles are associated 
with additional activation of thalamus, hippocampus, an-
terior cingulate and sensorimotor areas  [74, 76] . REM 
sleep is associated with activation of brainstem, thalami, 
anterior cingulate, mesial temporal and paralimbic areas 
and deactivation of posterior cingulate/precuneus, pari-
etal and inferior frontal areas  [51, 59, 60, 77] . These acti-
vation profiles overlap extensively with the DMN, but 
also show that activity shifts are not uniform across the 
network  [60] . Although the core function of the DMN 
remains controversial  [78] , it is known to mediate stimu-
lus-independent thought during wakefulness. Activation 
of the DMN during REM sleep is therefore plausible a 
priori, since dreaming is arguably the purest example of 
stimulus-independent thought  [46] . REM sleep is associ-
ated with specific alterations in DMN connectivity (in 
particular, reduced connectivity between posterior cin-
gulate and more anterior regions) and reduced reactivity 
to sensory stimuli, which together may mediate REM-
specific functions linked to ‘isolation’ of DMN subsys-
tems from the external environment  [59, 79] .
 Wakefulness tends to promote a net increase in synap-
tic strength, while sleep tends to attenuate synaptic 
strength  [20, 80, 81] , which is consistent with the known 
restorative and homeostatic functions of sleep. However, 
these sleep functions are unlikely to reflect the net direc-
tion of activity shifts alone. For example, wakefulness and 
REM sleep are associated with similar metabolic profiles, 
suggesting that the quality (and not merely the overall 
amount) of synaptic activity mediates the restorative func-
tions of the REM state. One potential expression of this 
qualitative alteration in synaptic drive may be a redistri-
bution of connectivity between components of the DMN 
 [79] . Although slow-wave (non-REM) sleep has generally 
been emphasised in synaptic homeostasis and downscal-
ing of synaptic networks potentiated during wakefulness, 
recent evidence suggests that REM sleep plays an impor-
tant role in these processes  [47] . In particular, REM sleep 
is associated electrophysiologically with a specific profile 
of phasic synchrony shifts in hippocampal subregions 
 [29] , providing a substrate for altered network synchrony, 
synaptic plasticity and information transfer which may be 
regionally specific  [52] . REM sleep deprivation in rats 
blocks expression of brain-derived neurotrophic factor 
 [48] , a key signalling molecule that modulates neural cir-
cuit activity and synaptic strength  [18] , while modafinil 
ameliorates the cognitive effects of REM deprivation in 
mice via increased expression of MMP-9, a gene impli-
cated in synaptic plasticity  [34] . We suggest that REM 
sleep may serve a crucial and active ‘rescue’ function in the 
repair of incipient neurodegenerative changes within syn-
aptic circuits concentrated in the DMN.
 REM sleep disruption early in the clinical course of AD 
is likely in part to result from degeneration of ascending 
cholinergic pathways, as these pathways are critical for 
initiating and maintaining REM sleep  [54] . Chronic sleep 
deprivation in rats has been associated with the formation 
of anti-nerve growth factor antibodies  [22] which, when 
infused into rat cerebral cortex, result in neurodegenera-
tion of cortical cholinergic boutons  [82] , and transgenic 
anti-NGF mice develop Alzheimer-like neurodegenera-
tion  [83] , suggesting a possible mechanism for sustained 
deleterious effects. The acetylcholinesterase inhibitor, 
donepezil, restores REM sleep in patients with mild-to-
moderate AD, and the magnitude of this effect correlates 
with cognitive benefit  [41] .
 Evidence for the Hypothesis: The Neuroanatomy 
of AD 
 Our understanding of AD neurobiology has been 
transformed by a substantial body of neuroimaging data 
which demonstrates that the neurodegenerative process 
has a predictable and regionally specific evolution in the 
brain  [1] . The very earliest disease targets in AD remain 
somewhat contentious but are likely to include entorhinal 
cortex and brainstem sites, including locus coeruleus, 
dorsal raphe nuclei or nucleus tractus solitarius  [2, 8, 84] . 
Consistent with the early disruption of circadian and 
sleep physiology observed clinically, neuropathological 
evidence in AD clearly implicates ascending brainstem 
pathways that govern the sleep-wake cycle at or near the 
outset of the disease, including cholinergic, dopaminer-
gic, melatoninergic and neurosteroid systems  [2, 4, 27, 42, 
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56, 63] . AD is a major cholinergic deficiency state  [66] , 
and cell loss in the nucleus basalis is correlated with the 
magnitude of cholinergic depletion in cerebral cortex 
 [73] . In addition, neuronal counts in the locus coeruleus 
are reduced by some 80% in AD  [57] , with marked atro-
phy of the suprachiasmatic nucleus  [67] . Involvement of 
the nucleus tractus solitarius could have particularly po-
tent effects, as this area serves as a major ‘signalling hub’, 
integrating brainstem functions with the circadian pace-
maker and widespread forebrain projection zones  [84] .
 The forebrain projection targets of the ascending path-
ways disrupted in AD are widely distributed in the cere-
bral cortex, thalamus and other subcortical structures. 
However, there is a precise segregation of targets accord-
ing to the specific transmitter systems involved  [73] . For 
example, in the case of the cholinergic system, the hippo-
campus, amygdala and paralimbic structures receive par-
ticularly dense cholinergic innervation, and subregional 
variations in the strength of cholinergic inputs are evident 
within these structures. Furthermore, cholinergic projec-
tions to particular structures originate in distinct cholin-
ergic neuronal pools in the brainstem and basal forebrain. 
This stratified organisation would support the mnestic 
functions mediated by the cholinergic system in the 
healthy brain and suggests a general mechanism for ‘gat-
ing’ sensory information to the limbic system  [73] . In 
pathophysiological terms, such anatomical differentia-
tion provides a potential substrate for the regionally di-
rected spread of pathology in AD, effectively ‘focusing’ 
the neurodegenerative process on vulnerable zones in the 
DMN and potentially establishing a gradient of regional 
vulnerability across the network (see  fig. 1 ).
 Early involvement of brainstem neurotransmitter sys-
tems may therefore explain the integral vulnerability of 
the DMN in AD  [6, 8, 12, 53] . Neurotransmitter cycling 
is closely linked to neural activity  [54] , suggesting that 
altered patterns of neural activity in the DMN projection 
zones of damaged neurotransmitter pathways may gov-
ern the expression of AD. The evidence we have present-
ed above demonstrates that sleep-wake cycling is a par-
ticularly potent example of large-scale alterations in neu-
ral activity focused in the DMN.
 Evidence for the Hypothesis: Cellular and Molecular 
Links between Sleep and Neurodegeneration 
 Previous animal work has suggested that altered pat-
terns of sleep-wake activity may directly promote neuro-
degenerative brain damage and these effects could oper-
ate early in the pathophysiological cascade. Increased 
apoptosis, cytoskeletal disintegration and neuronal loss 
have been observed in the locus coeruleus of rat brain af-
ter REM sleep deprivation  [44] . Neurons in the dorsal 
raphe nucleus may increase in size after REM sleep depri-
vation as a partial compensatory response to injury and 
(if not reversed) a potential prerequisite for neurodegen-
eration  [44] . Cell size can be normalised by prazosin, sug-
gesting that the response is mediated by noradrenergic 
pathways  [44] .
 At a molecular level, potential links between sleep-re-
lated activity and substrates for neurodegenerative dam-
age have been identified. Disrupted circadian function in 
mouse models with reduced expression of clock gene pro-
teins (key regulators of circadian rhythm) is associated 
with accelerated ageing and impaired cognition via sleep-
dependent and sleep-independent effects  [27] . Sleep du-
ration has been shown to be linearly related to telomere 
length in men, suggesting that in human subjects chronic 
sleep deprivation may also accelerate ageing  [85] . In rat 
cerebral cortex, chronic sleep deprivation has a unique 
molecular profile of gene upregulation compared with 
shorter-term sleep deprivation  [22] . More specifically, 
genetic factors may link sleep disruption with the patho-
physiology of AD. While the effect of apolipoprotein E 
status has been inconsistent  [58, 67] , both increased sus-
ceptibility to sleep disturbance in AD  [58] and overall risk 
of developing AD  [86] have been linked to polymor-
phisms of the gene-coding monoamine oxidase A, which 
helps govern the availability of serotonin in melatonin 
synthesis. This genetic factor also provides a potential 
link to mood disturbance, in line with evidence that de-
pressive episodes can predict subsequent development of 
AD  [40] .
 At a cellular and synaptic level, how might sleep dis-
turbance promote AD-associated pathophysiological al-
terations and, ultimately, neurodegeneration? Several 
general candidate mechanisms have been identified. 
These mechanisms interact and can be broadly consid-
ered as pro-inflammatory, pro-fibrillogenic and mis-
communicative.
 The changes in sleep circuitry and associated neu-
rotransmitters in AD have pro-inflammatory effects. This 
pro-inflammatory state could have reciprocal pathogenic 
interactions with specific brainstem hub regions  [84] . 
Sleep disruption is associated with dysregulation of the 
physiological stress response with altered secretion of cor-
tisol and other neurosteroids, and these substances in turn 
modulate cholinergic functions  [27, 42] . In addition, sleep 
disruption leads to reduced cellular tolerance of oxidation 
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stress, which in turn is likely to reflect loss of neuroprotec-
tive functions, increased generation of reactive oxygen 
species, altered transduction of intracellular metabolic 
signals and reduced DNA repair  [27, 87] . The outcome of 
this cascade is neuronal dysfunction and death. The cas-
cade may be triggered by an AD-associated reduction in 
the release of melatonin  [50] . A pro-inflammatory mecha-
nism of cell death may operate in various disease process-
es (it may, for example, account for the finding of acceler-
ated hippocampal atrophy in obstructive sleep apnoea, 
perhaps mediated by phasic hypoxia)  [88, 89] . AD speci-
ficity would, however, emerge both in the initial sequence 
of cellular events that triggers the pro-inflammatory cas-
cade and in the anatomical configuration of the pathways 
that are primarily damaged by the cascade (see  fig. 1 ).
 Sleep disruption in AD is likely to promote deposition 
of pathogenic fibrillar proteins. Synaptic activity has been 
shown using in vivo microdialysis to regulate levels of 
β-amyloid in interstitial fluid  [45] . More specifically, in 
transgenic APP mice, sleep deprivation is associated with 
increased levels of interstitial fluid β-amyloid and, subse-
quently, increased deposition of amyloid plaques, while 
sleep induction with an orexin antagonist decreases 
plaque burden relative to control mice  [26] . In human 
subjects, the diurnal level of β-amyloid-42 (the soluble 
oligomeric species implicated in generating amyloid 
plaques) in cerebrospinal fluid (CSF) is increased by 
wakefulness and decreased by sleep  [24] , while the level 
of β-amyloid in interstitial fluid is regulated by endoge-
nous neuronal activity (as indexed by lactate production) 
 [45] . Manipulation of synaptic vesicle release affects 
β-amyloid levels in interstitial fluid, suggesting a direct 
mechanistic link  [45] . Conversely, both the diurnal fluc-
tuation of CSF β-amyloid levels and the sleep-wake cycle 
can be normalised by immunisation against β-amyloid-42 
in transgenic mouse models of AD  [33] . Melatonin has 
anti-fibrillary actions  [31] and inhibits deposition of 
β-amyloid and development of cognitive deficits in mouse 
models of AD  [23, 27, 28] . Although clinical trials of mel-
atonin have had somewhat mixed results  [90–92] , there 
is some evidence that it can delay deposition of β-amyloid 
in mouse models, improve survival in mouse models of 
AD  [28] , and improve cognition in patients with mild 
cognitive impairment  [38] . Effects of sleep-wake altera-
tions on pathogenic protein deposition are not restricted 
to β-amyloid. A similar link has been demonstrated for 
protein tau, the other major culprit protein implicated in 
AD pathogenesis. In mice, tau content is increased in the 
pons, preoptic area and hippocampus after 24 h of REM 
sleep deprivation and in the frontal cortex after 72 h of 
REM sleep deprivation  [32] . These findings suggest that 
sleep disruption may lead to tissue-specific alteration in 
the neural cytoskeleton associated with protein tau depo-
sition. In murine models of sleep deprivation there is ev-
idence of an adaptive response to accumulated misfolded 
proteins which involves upregulation of unfolded protein 
response mechanisms in the endoplasmic reticulum. This 
adaptive response is impaired in aged mice, leading to ac-
cumulation of misfolded proteins and accelerating the 
proapoptotic cascade  [30] .
 A further possible mechanism that could link sleep dis-
ruption to neurodegeneration is alteration in the pattern 
of synaptic activity, leading to neuronal miscommunica-
tion  [10] . This is presently the least well worked out of the 
candidate mechanisms we consider, but might potential-
ly precede and instigate pro-inflammatory and pro-fibril-
lary cascades. Furthermore, it provides a potential modus 
operandi for the trans-synaptic spread of pathology across 
the vulnerable network, an emerging principle that is like-
ly to be relevant to the evolution of a range of neurode-
generative diseases  [9] . We propose that neuronal mis-
communication across synapses may be the fundamental 
mechanism underpinning the hypnic hypothesis of AD, 
leading processes of frank degeneration. Cellular mis-
communication need not be restricted to neurons; it 
might also blight neuronal-glial interactions  [10] . Abnor-
mal or inefficient synaptic activity could restrict delivery 
of trophic factors or promote intercellular transfer of mis-
folded pathogenic proteins  [10] . Diffusive or ‘prion-like’ 
spread of pathogenic proteins has been demonstrated in 
animal models for both β-amyloid  [16] and tau  [15] . In 
addition, altered synaptic activity might itself promote lo-
cal protein misfolding in the presence of pre-toxic sub-
strates (e.g. enhanced tau phosphorylation via increased 
nerve growth factor release  [4] ) or might exert less spe-
cific excitotoxic effects (e.g. by triggering the pro-inflam-
matory cascade). Once present, pathogenic proteins may 
further degrade synaptic function. For example, β-amyloid 
fragments may alter synaptic transmission via an AMPA-
mediated glutamatergic mechanism  [93] , while tau mod-
ulates the synchronous firing of neurones  [94] .
 The mechanisms we have considered would have 
many potential points of convergence and amplification 
(see  fig. 1 ). For example, melatonin, in addition to its neu-
roprotective and anti-fibrillary effects, enhances cholin-
ergic function  [95] . Melatonin deficiency would therefore 
tend to promote abnormal activity at cholinergic synaps-
es. Increased neuronal activity may promote accumula-
tion of β-amyloid  [7] , while deposition of β-amyloid in 
turn disrupts synaptic function  [6, 96] . The pro-inflam-
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matory cascade may reduce clearance of pathogenic pro-
teins, thereby accelerating fibrillary transformation, and 
may also inhibit synaptic repair  [10] . Once the neurode-
generative process in AD becomes established, the pro-
oxidant state would be perpetuated by the deposition of 
amyloid plaques and neurofibrillary tangles. Pathogenic 
proteins may act to consolidate and perpetuate the abnor-
mal toxic state (e.g. protein tau itself may indirectly regu-
late the sleep-wake cycle)  [94] .
 Testing the Hypothesis 
 We propose this hypnic hypothesis of AD with cave-
ats. Despite recent progress, our understanding of sleep 
neurobiology and AD pathophysiology remains limited. 
In particular, the mechanisms that link molecular and 
cellular events to neural circuit damage remain to be es-
tablished in detail. We do not, of course, propose that 
sleep disturbance is the sole factor driving the develop-
ment of AD – rather, we envisage it as a key factor in con-
solidating and amplifying the neurodegenerative process 
in core vulnerable brain areas. Taking these caveats into 
account, the hypnic hypothesis makes certain specific 
predictions with potentially far-reaching implications 
that might be tested in future work (summarised in  ta-
ble 1 ). The hypothesis implies, for example, that chronic 
sleep disruption might promote the development of AD 
and, conversely, that appropriate treatment to regularise 
sleep patterns, in particular to augment REM sleep, might 
prevent (or at least retard) its development. Arguably, any 
hypnic effect might be relatively more important early in 
the evolution if AD, before the neurodegenerative process 
is fully established and secondary pathogenic mecha-
nisms have come into play. Aside from its importance in 
establishing the pathophysiological sequence, early-stage 
disease is a more feasible candidate for detailed polysom-
nographic studies than established dementia.
 Perhaps the most basic requirement will be a detailed, 
prospective longitudinal analysis to track sleep physiol-
ogy in relation to early markers of disease onset (ideally, 
predating the development of cognitive decline). This 
would be logistically challenging but could be directed to 
cohorts at known risk of developing AD (e.g. carriers of 
disease-causing mutations), capitalising on recent prog-
ress in identifying novel biomarkers of AD such as CSF 
tau, β-amyloid assays and amyloid brain imaging, as well 
as laboratory markers of circadian function (such as mel-
atonin). There is a particular need to investigate REM 
sleep and dreaming in AD, about which information re-
mains very limited. Complementary approaches should 
include large-scale clinical epidemiological studies to as-
sess relative AD risk associated with habitual sleep pat-
terns (e.g. those associated with particular occupations) 
and, potentially, therapeutic trials of sleep-regularising 
agents, if these can be administered sufficiently early in 
the course of disease. Ultimately, detailed pathological 
correlation will be required in individuals with AD un-
dergoing comprehensive assessment of sleep physiology 
during life.
 More fundamentally, the pathophysiology of sleep re-
mains to be worked out in detail at cellular and circuit 
levels. This will entail the development of animal and in 
vitro models that can capture the effects of AD patholo-
gy, the effects of perturbed cellular interactions on the 
spread of AD pathology in model neural circuits, and 
compensatory cellular and synaptic responses. Animal 
models also allow evaluation of the impact of specific 
manipulations of sleep physiology (e.g. selective REM 
deprivation or augmentation) on molecular and behav-
ioural phenotypes. In addition, more information is 
needed about early markers of DMN pathophysiology. 
This might entail, for example, an analysis of complex 
behavioural alterations (potentially expressed in social, 
affective or mood changes) that are not conventionally 
regarded as part of the typical phenotype of established 
AD but which may well go under-recognised  [40] . Ani-
mal models are potentially particularly valuable for 
charting the evolution of circadian disturbances in rela-
tion to neurodegenerative pathology and the effects of 
interventions  [25] .
 Finally, we speculate that the hypnic hypothesis of AD 
might exemplify a much broader class of disease mecha-
nisms, namely, neurodegeneration instigated by abnor-
mal neural network behaviour. Sleep illustrates a gross 
and pervasive alteration in brain function. It remains to 
be established whether more subtle, habitual patterns of 
brain activity might promote other kinds of pathophysi-
ological deterioration. Examples might include the cogni-
tive patterns associated with certain occupations, which 
have been associated epidemiologically with particular 
neurodegenerative syndromes  [97] , or the role of educa-
tional attainment  [54] . Consistent with this notion, sen-
sorially enriched environments have been shown to affect 
the development of the neurodegenerative process (as in-
dexed by rates of deposition of amyloid plaques) in animal 
models of AD  [98–100] . These effects may be mediated in 
part by exercise-associated influences on cholinergic ac-
tivity and neuronal plasticity  [101] . If we are to explain the 
syndromic specificity of particular neurodegenerative pa-
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thologies, it is critical that we uncover the processes that 
link molecular lesions to large-scale network disintegra-
tion  [9] . The functional properties of neural circuits and 
their modes of operation in generating complex (includ-
ing circadian) behaviours are a largely unexplored but po-
tentially critical link by which cellular events might im-
print and propagate themselves across vulnerable net-
works at the level of the whole brain. The creation of 
programmable neural networks in vivo offers the exciting 
prospect of assessing such processes directly  [102] .
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